Hypera SA
BOVESPA:HYPE3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hypera SA
Pre-Tax Income
Hypera SA
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Hypera SA
BOVESPA:HYPE3
|
Pre-Tax Income
R$900.1m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
9%
|
|
|
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
|
Pre-Tax Income
R$219.3m
|
CAGR 3-Years
14%
|
CAGR 5-Years
19%
|
CAGR 10-Years
10%
|
|
Hypera SA
Glance View
Hypera S.A., a leading force in the Brazilian pharmaceuticals market, has carved a niche by catering to a wide spectrum of health needs through a diverse portfolio. Originally established under the name Hypermarcas, the company took root with the ambition of becoming a pharmaceutical powerhouse in Brazil. This vision was set in motion through strategic organic growth and a series of savvy acquisitions, which helped consolidate its offerings across over-the-counter (OTC) medications, branded prescriptions, dermo-cosmetics, and generics. Each of these segments represents a cog in the machine that drives Hypera’s profitability, with its robust pipeline of drug innovations and strong brand presence ensuring a steady flow of revenue. What truly sets Hypera apart is its ability to harness the synergies between its diverse product lines and an extensive distribution network across Brazil. The company generates revenue not only by selling pharmaceuticals directly to consumers but also through collaborations with healthcare professionals and pharmacies, ensuring its products reach a vast market. Hypera’s commitment to research and development further fuels its growth engine, as it continuously seeks to introduce new drugs and treatments that meet the evolving healthcare demands. The company’s strategic focus on operational efficiency and cost management underpins its financial performance, while its strong brand recognition makes it a preferred choice among consumers and medical professionals alike in Brazil’s dynamic healthcare environment.
See Also
What is Hypera SA's Pre-Tax Income?
Pre-Tax Income
900.1m
BRL
Based on the financial report for Dec 31, 2025, Hypera SA's Pre-Tax Income amounts to 900.1m BRL.
What is Hypera SA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
9%
Over the last year, the Pre-Tax Income growth was -8%. The average annual Pre-Tax Income growth rates for Hypera SA have been -18% over the past three years , -6% over the past five years , and 9% over the past ten years .